GlaxoSmithKline/Theravance's Anoro Ellipta is Most Likely to Replace Boehringer Ingelheim's Spiriva Among COPD Patients, Accord

     GlaxoSmithKline/Theravance's Anoro Ellipta is Most Likely to Replace
    Boehringer Ingelheim's Spiriva Among COPD Patients, According to U.S.

Sales of the LABA/LAMA Combination Drug Class are Expected to Grow
Significantly Over the Next Six Months, According to Findings from Decision
Resources Group

PR Newswire

BURLINGTON, Mass., Aug. 26, 2014

BURLINGTON, Mass., Aug. 26, 2014 /PRNewswire/ -- Decision Resources Group
finds that two-thirds of surveyed pulmonologists indicate that Boehringer
Ingelheim's Spiriva is the agent most likely to be replaced by
GlaxoSmithKline/Theravance's first-in-class LABA/LAMA combination Anoro
Ellipta. To date, surveyed physicians reported that, of the Anoro Ellipta
patients who were switched from another COPD agent, two-thirds were switched
from Spiriva.

Decision Resources Group Logo.

Other key findings from the report entitled LaunchTrends Anoro Ellipta (Wave
1) 2014:

  oUse of LABA/LAMAs to triple: Pulmonologists expect their use of the
    LABA/LAMA drug class to nearly triple in the next six months.
  oReplacing Spiriva with Anoro Ellipta: The fact that a majority of
    physicians plan to use this drug class as a second-line agent explains why
    many pulmonologists anticipate replacing Spiriva with Anoro Ellipta.
    Spiriva is a LAMA which constitutes only one portion of Anoro Ellipta's
    LABA/LAMA combination.
  oAnoro Ellipta's main benefit: Almost half of pulmonologists indicated that
    the main benefit of Anoro Ellipta is that it is the first LABA/LAMA
    combination drug approved in the United States.
  oAnoro Ellipta's greatest disadvantage: Cost is believed to be the single
    greatest disadvantage of Anoro Ellipta, according to nearly one-quarter of

Comments from Decision Resources Group Analyst Jen Dolga:

  o"Although cost is cited as the greatest disadvantage of Anoro Ellipta in
    Wave 1 of this study, it is possible that when physicians become more
    familiar with the combination inhaler and take into consideration the fact
    that patients are only paying one fee for the combination inhaler rather
    than paying for a LABA and a LAMA separately, we may see a decline in the
    percentage of pulmonologists who list cost as the ultimate drawback."
  o"It will be interesting to see how much patient share is taken over by
    this new combination inhaler over the next few months. Even more
    fascinating will be watching how rapidly the COPD market changes as other
    LABA/LAMA combination drugs in development become approved."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and
insights on critical issues within the healthcare industry. Clients rely on
this analysis and data to make informed decisions. Find out more at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo -

SOURCE Decision Resources Group

Press spacebar to pause and continue. Press esc to stop.